Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
LXRX 
Lexicon Pharmaceuticals Inc (LXRX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/14/2025: LXRX (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
5 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $2.58
1 Year Target Price $2.58
| 1 | Strong Buy |
| 2 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 47.37% | Avg. Invested days 33 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 07/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 392.23M USD | Price to earnings Ratio - | 1Y Target Price 2.58 |
Price to earnings Ratio - | 1Y Target Price 2.58 | ||
Volume (30-day avg) 5 | Beta 1.01 | 52 Weeks Range 0.28 - 2.45 | Updated Date 07/14/2025 |
52 Weeks Range 0.28 - 2.45 | Updated Date 07/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.5 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -2034.79% |
Management Effectiveness
Return on Assets (TTM) -28.88% | Return on Equity (TTM) -86.09% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 299136240 | Price to Sales(TTM) 12.57 |
Enterprise Value 299136240 | Price to Sales(TTM) 12.57 | ||
Enterprise Value to Revenue 9.58 | Enterprise Value to EBITDA -2.58 | Shares Outstanding 363177984 | Shares Floating 183670010 |
Shares Outstanding 363177984 | Shares Floating 183670010 | ||
Percent Insiders 1.17 | Percent Institutions 74.92 |
Upturn AI SWOT
Lexicon Pharmaceuticals Inc
Company Overview
History and Background
Lexicon Pharmaceuticals, Inc. was founded in 1995. It's a biopharmaceutical company focused on discovering, developing, and commercializing innovative medicines to treat diseases.
Core Business Areas
- Drug Discovery and Development: Lexicon uses its gene knockout technology to identify and validate drug targets. They focus on developing small molecule drugs.
- Commercialization: Lexicon commercializes its own products, either independently or through partnerships.
Leadership and Structure
Lonnel Coats is the CEO. The company has a typical corporate structure with a board of directors and various departments (R&D, commercial, etc.).
Top Products and Market Share
Key Offerings
- XERMELO (telotristat ethyl): XERMELO is used to treat carcinoid syndrome diarrhea in adults. Competitors include generic options and other therapies managing symptoms of carcinoid syndrome. Specific market share data is not readily available without subscription-based market analysis tools, however it is a leading treatment in the class.
- Sotagliflozin (Zynquista - partnered with Sanofi, rights returned to Lexicon): Sotagliflozin was developed for the treatment of diabetes (both type 1 and type 2). Sanofi originally marketed and sold the treatment, but the rights have returned to Lexicon. Competitors include other SGLT2 inhibitors such as Jardiance (empagliflozin) and Farxiga (dapagliflozin). Market share data not readily available.
Market Dynamics
Industry Overview
The pharmaceutical industry is highly competitive and regulated. Companies are always researching novel treatments for many diseases.
Positioning
Lexicon is a mid-sized biopharmaceutical company with a focus on novel mechanisms of action. Competitive advantages include their drug discovery platform and specialized focus.
Total Addressable Market (TAM)
The TAM for treatments that Lexicon Pharmaceuticals are developing is estimated to be over $40 billion. Lexicon is positioned to capture a percentage of the TAM through focused drug development.
Upturn SWOT Analysis
Strengths
- Proprietary drug discovery platform
- Experienced management team
- Approved product (Xermelo)
- Returning rights to Sotagliflozin provides greater flexibility and potential commercial opportunities.
Weaknesses
- Limited financial resources compared to larger pharma companies
- Dependence on a few key products
- History of partnerships and the return of rights can impact market confidence
Opportunities
- Expanding indications for Xermelo
- Developing new drugs using their platform
- Partnerships with larger pharmaceutical companies
- Advancements in gene knockout technology
Threats
- Competition from larger pharmaceutical companies
- Regulatory hurdles
- Clinical trial failures
- Generic competition for Xermelo (once patents expire)
- Market access challenges and pricing pressures
Competitors and Market Share
Key Competitors
- NBIX
- VRTX
- AMGN
Competitive Landscape
Lexicon is a smaller player compared to the larger pharmaceutical companies. Its advantage lies in its drug discovery platform, while its disadvantages are limited resources and reliance on partnerships.
Growth Trajectory and Initiatives
Historical Growth: Requires detailed financial data to assess revenue growth, product sales, etc.
Future Projections: Future growth projections are based on analyst estimates and require access to financial analysis tools.
Recent Initiatives: Recent initiatives include new clinical trials, partnerships, and regulatory submissions.
Summary
Lexicon Pharmaceuticals is a biopharmaceutical company with a proprietary drug discovery platform and an approved product, Xermelo. Its future success depends on successful clinical trials and commercialization efforts. Competition from larger pharmaceutical companies and regulatory hurdles are key challenges it must overcome. Financial stability and strategic partnerships will be critical for its continued growth.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Press Releases
- Analyst Reports (FactSet, etc.) - Requires Subscription
- Market Research Reports (e.g., EvaluatePharma) - Requires Subscription
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Market share data is estimates and may not be precise. Financial data requires access to subscription-based services.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Lexicon Pharmaceuticals Inc
Exchange NASDAQ | Headquaters The Woodlands, TX, United States | ||
IPO Launch date 2000-04-07 | CEO & Director Dr. Michael S. Exton Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 103 | Website https://www.lexpharma.com |
Full time employees 103 | Website https://www.lexpharma.com | ||
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company offers Sotagliflozin, an orally-delivered small molecule drug to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visits in adults with heart failure or type 2 diabetes mellitus, chronic kidney disease or CKD, and other cardiovascular risk factors. Its orally-delivered small molecule drug candidates under development include sotagliflozin for the treatment of hypertrophic cardiomyopathy or HCM and type 1 diabetes that is in Phase 3 clinical trial; LX9211, which has completed Phase II clinical trials for the treatment of neuropathic pain; and LX9851 for the treatment of obesity and associated cardiometabolic disorders, as well as for weight management. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Viatris Inc. and Bristol-Myers Squibb Company. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.